For the Haemophilia Surveillance System Investigators.
ORIGINAL ARTICLE Clinical haemophilia
Prevalence of malignancies among U.S. male patients with haemophilia: a review of the Haemophilia Surveillance System
Article first published online: 8 JAN 2012
© 2012 Blackwell Publishing Ltd
Volume 18, Issue 4, pages 532–539, July 2012
How to Cite
DUNN, A. L., AUSTIN, H. and MICHAEL SOUCIE, J. (2012), Prevalence of malignancies among U.S. male patients with haemophilia: a review of the Haemophilia Surveillance System. Haemophilia, 18: 532–539. doi: 10.1111/j.1365-2516.2011.02731.x
The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
- Issue published online: 1 JUL 2012
- Article first published online: 8 JAN 2012
- Accepted after revision 2 December 2011
- cancer, haemophilia, leukemia, malignancy, prevalence, surveillance
Summary. The prevalence of malignancies in US male patients with haemophilia, with or without concomitant viral infections, remains unknown. To estimate the prevalence of malignancy in US male patients with haemophilia. We investigated the prevalence of malignancies among male patients with haemophilia using data from a six-state haemophilia surveillance project. Case patients with malignancies were identified using International Classification of Diseases, 9th Revision, Clinical Modification codes abstracted from hospital records and death certificates during the surveillance period. Cancer prevalence rates were calculated for each year during the surveillance and compared with age- and race-specific prevalence rates among the U.S. male population obtained from the Surveillance, Epidemiology and End Results (SEER) Program. A total of 7 cases of leukaemia, 23 cases of lymphoma and 56 classifiable solid malignancies were identified among 3510 case patients during a total of 15 330 annual data abstraction collections. The rates of leukaemia, lymphoma and liver cancer among case patients were significantly higher than the rates among U.S. males as judged by prevalence ratios of 3.1 [95% confidence interval (CI) = 1.4–7.0] and 2.9 (95% CI = 1.8–4.6), respectively. In contrast, the prevalence ratio of prostate cancer was lower than expected at 0.49 (95% CI = 0.31–0.77). Overall the prevalence of most cancers among case patients was similar to that of the U.S. male population. However, patients with haemophilia who have unexplained symptoms should be evaluated for malignancy.